Personal information

No personal information available

Activities

Employment (1)

University of Washington: Seattle, WA, US

1999-07-15 to present | Professor (Ob/Gyn)
Employment
Source: Self-asserted source
Elizabeth Swisher

Works (50 of 54)

Items per page:
Page 1 of 2

Gynecologic cancer clinical trial eligibility criteria as a marker for equitable clinical trial access

2024-12-17 | Other
Contributors: Ann Oluloro; Elizabeth M. Swisher; Heidi J. Gray; Barbara Goff; Kemi M. Doll
Source: check_circle
Crossref

The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial

Nature Communications
2024-03-30 | Journal article
Contributors: Elena Giudice; Tzu-Ting Huang; Jayakumar R. Nair; Grant Zurcher; Ann McCoy; Darryl Nousome; Marc R. Radke; Elizabeth M. Swisher; Stanley Lipkowitz; Kristen Ibanez et al.
Source: check_circle
Crossref

BLM overexpression as a predictive biomarker for CHK1 inhibitor response in PARP inhibitor–resistant BRCA -mutant ovarian cancer

Science Translational Medicine
2023-06-21 | Journal article
Contributors: Nitasha Gupta; Tzu-Ting Huang; Jayakumar R. Nair; Daniel An; Grant Zurcher; Erika J. Lampert; Ann McCoy; Ashley Cimino-Mathews; Elizabeth M. Swisher; Marc R. Radke et al.
Source: check_circle
Crossref

Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Supplementary Data from Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

2023-04-03 | Preprint
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref

Appendix from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Appendix from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

2023-03-31 | Preprint
Contributors: Erika J. Lampert; Alexandra Zimmer; Michelle Padget; Ashley Cimino-Mathews; Jayakumar R. Nair; Yingmiao Liu; Elizabeth M. Swisher; James W. Hodge; Andrew B. Nixon; Erin Nichols et al.
Source: check_circle
Crossref

Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

2023-03-31 | Preprint
Contributors: Erika J. Lampert; Alexandra Zimmer; Michelle Padget; Ashley Cimino-Mathews; Jayakumar R. Nair; Yingmiao Liu; Elizabeth M. Swisher; James W. Hodge; Andrew B. Nixon; Erin Nichols et al.
Source: check_circle
Crossref

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Data from Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer

2023-03-31 | Preprint
Contributors: Cassandra L. Moyer; Jennifer Ivanovich; Jessica L. Gillespie; Rachel Doberstein; Marc R. Radke; Marcy E. Richardson; Scott H. Kaufmann; Elizabeth M. Swisher; Paul J. Goodfellow
Source: check_circle
Crossref

Data from Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer

2023-03-31 | Preprint
Contributors: Cassandra L. Moyer; Jennifer Ivanovich; Jessica L. Gillespie; Rachel Doberstein; Marc R. Radke; Marcy E. Richardson; Scott H. Kaufmann; Elizabeth M. Swisher; Paul J. Goodfellow
Source: check_circle
Crossref

Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

2023-03-31 | Preprint
Contributors: Erika J. Lampert; Alexandra Zimmer; Michelle Padget; Ashley Cimino-Mathews; Jayakumar R. Nair; Yingmiao Liu; Elizabeth M. Swisher; James W. Hodge; Andrew B. Nixon; Erin Nichols et al.
Source: check_circle
Crossref

Supplementary Data from Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study

2023-03-31 | Preprint
Contributors: Erika J. Lampert; Alexandra Zimmer; Michelle Padget; Ashley Cimino-Mathews; Jayakumar R. Nair; Yingmiao Liu; Elizabeth M. Swisher; James W. Hodge; Andrew B. Nixon; Erin Nichols et al.
Source: check_circle
Crossref

Supplementary Data from Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer

2023-03-31 | Preprint
Contributors: Cassandra L. Moyer; Jennifer Ivanovich; Jessica L. Gillespie; Rachel Doberstein; Marc R. Radke; Marcy E. Richardson; Scott H. Kaufmann; Elizabeth M. Swisher; Paul J. Goodfellow
Source: check_circle
Crossref

Supplementary Data from Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer

2023-03-31 | Preprint
Contributors: Cassandra L. Moyer; Jennifer Ivanovich; Jessica L. Gillespie; Rachel Doberstein; Marc R. Radke; Marcy E. Richardson; Scott H. Kaufmann; Elizabeth M. Swisher; Paul J. Goodfellow
Source: check_circle
Crossref

Table S1 and Table S2 from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Table S1 and Table S2 from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Table S2 from Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer

2023-03-31 | Preprint
Contributors: Cassandra L. Moyer; Jennifer Ivanovich; Jessica L. Gillespie; Rachel Doberstein; Marc R. Radke; Marcy E. Richardson; Scott H. Kaufmann; Elizabeth M. Swisher; Paul J. Goodfellow
Source: check_circle
Crossref

Table S2 from Rare <i>BRIP1</i> Missense Alleles Confer Risk for Ovarian and Breast Cancer

2023-03-31 | Preprint
Contributors: Cassandra L. Moyer; Jennifer Ivanovich; Jessica L. Gillespie; Rachel Doberstein; Marc R. Radke; Marcy E. Richardson; Scott H. Kaufmann; Elizabeth M. Swisher; Paul J. Goodfellow
Source: check_circle
Crossref

An Accessible Communication System for Population-Based Genetic Testing: Development and Usability Study

JMIR Formative Research
2022-10-17 | Journal article
Contributors: Tara Coffin; Deborah Bowen; Elizabeth Swisher; Karen Lu; Nadine Rayes; Barbara Norquist; Stephanie Blank; Douglas Levine; Jamie Bakkum-Gamez; Gini Fleming et al.
Source: check_circle
Crossref

Using Social Media to Facilitate Communication About Women’s Testing: Tool Validation Study

JMIR Formative Research
2022-09-26 | Journal article
Contributors: Tara Coffin; Deborah Bowen; Karen Lu; Elizabeth M Swisher; Nadine Rayes; Barbara Norquist; Stephanie V Blank; Douglas A Levine; Jamie Nadine Bakkum-Gamez; Gini F Fleming et al.
Source: check_circle
Crossref

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research
2021-12-01 | Journal article
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

PolyG-DS: An ultrasensitive polyguanine tract–profiling method to detect clonal expansions and trace cell lineage

Proceedings of the National Academy of Sciences
2021-08-03 | Journal article
Contributors: Yuezheng Zhang; Brendan F. Kohrn; Ming Yang; Daniela Nachmanson; T. Rinda Soong; I-Hsiu Lee; Yong Tao; Hans Clevers; Elizabeth M. Swisher; Teresa A. Brentnall et al.
Source: check_circle
Crossref

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

Nature Communications
2021-05-03 | Journal article
Contributors: Elizabeth M. Swisher; Tanya T. Kwan; Amit M. Oza; Anna V. Tinker; Isabelle Ray-Coquard; Ana Oaknin; Robert L. Coleman; Carol Aghajanian; Gottfried E. Konecny; David M. O’Malley et al.
Source: check_circle
Crossref

Long-term survival of an ovarian cancer patient harboring a RAD51C missense mutation

Molecular Case Studies
2021-04 | Journal article
Contributors: Meghan R. Sullivan; Rohit Prakash; Yashpal Rawal; Weibin Wang; Patrick Sung; Marc R. Radke; Scott H. Kaufmann; Elizabeth M. Swisher; Kara A. Bernstein; Maria Jasin
Source: check_circle
Crossref

Targeting BET Proteins BRD2 and BRD3 in Combination with PI3K-AKT Inhibition as a Therapeutic Strategy for Ovarian Clear Cell Carcinoma

Molecular Cancer Therapeutics
2021-04-01 | Journal article
Contributors: Shogo Shigeta; Goldie Y.L. Lui; Reid Shaw; Russell Moser; Kay E. Gurley; Grace Durenberger; Rachele Rosati; Robert L. Diaz; Tan A. Ince; Elizabeth M. Swisher et al.
Source: check_circle
Crossref
Items per page:
Page 1 of 2

Peer review (1 review for 1 publication/grant)

Review activity for Cell. (1)